The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry join their forces for: – creating a common platform of knowledge and language for early stage researchers (ESR) working in the Drug Discovery and Development area aiming to convey complementary pharma-skills – exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry – establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on. To achieve the above objectives the main tasks of MoGlyNet are: – to train 12 ESRs in joint academic/industrial program of cutting-edge training-by-research, high quality supervision, complementary and transferable Pharma-skills training, inter-network secondments, and workshops/Summer Schools – to pursue an innovative research project that tackle a timely and important scientific problem with a multidisciplinary approach (from molecular modelling to in vivo studies). Atherosclerosis is an aging-related disease and our research approach for a better therapy of atherosclerosis will be focused on an enzymatic target, a key player in glycolysis/oxidative stress and therefore in pathological angiogenesis – to build a solid foundation for long-term European excellence in this field by disseminating MoGlyNet research/training outcomes and best practice into the partners Doctoral Schools, and by fostering long-term partnerships and collaborations that will outlast the Consortium – to transfer expertise/know-how among the Consortium participants and to external groups via networking activities, intersectorial exposure, secondments, workshops, sharing of learning material, public engagement and outreach activities.

MOGLYNET – Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study – H2020 / A. Corsini, A. Contini, G. De Meyer, M.L. Gelmi, M. Carini, M. Cascante, M. Zanda, P. Quax, S. Bellosta, W. Martinet. - In: IMPACT. - ISSN 2398-7073. - 2017:8(2017 Oct), pp. 26-28. [10.21820/23987073.2017.8.26]

MOGLYNET – Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study – H2020

A. Corsini
Primo
;
A. Contini
Secondo
;
M.L. Gelmi;M. Carini;S. Bellosta
Penultimo
;
2017-10

Abstract

The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry join their forces for: – creating a common platform of knowledge and language for early stage researchers (ESR) working in the Drug Discovery and Development area aiming to convey complementary pharma-skills – exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry – establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on. To achieve the above objectives the main tasks of MoGlyNet are: – to train 12 ESRs in joint academic/industrial program of cutting-edge training-by-research, high quality supervision, complementary and transferable Pharma-skills training, inter-network secondments, and workshops/Summer Schools – to pursue an innovative research project that tackle a timely and important scientific problem with a multidisciplinary approach (from molecular modelling to in vivo studies). Atherosclerosis is an aging-related disease and our research approach for a better therapy of atherosclerosis will be focused on an enzymatic target, a key player in glycolysis/oxidative stress and therefore in pathological angiogenesis – to build a solid foundation for long-term European excellence in this field by disseminating MoGlyNet research/training outcomes and best practice into the partners Doctoral Schools, and by fostering long-term partnerships and collaborations that will outlast the Consortium – to transfer expertise/know-how among the Consortium participants and to external groups via networking activities, intersectorial exposure, secondments, workshops, sharing of learning material, public engagement and outreach activities.
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
art00010.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 304.56 kB
Formato Adobe PDF
304.56 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/630975
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact